Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASIT sequential chemotherapy and immunotherapy for locally advanced urothelial cancer
NL-OMON53642Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in transitional cell carcinoma (TCC), bladder cancer, upper tract urothelial carcinoma (UTUC) and 1 more, sponsored by Erasmus MC. Primary endpoint: Pathological complete response rate. Started Feb 2023; status: recruiting.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancerupper tract urothelial carcinoma (UTUC)urethral cancer
Beyond the preview
Go deeper on NL-OMON53642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53642.